Out-of-pocket costs for AstraZeneca’s inhaled respiratory therapies — most of which are used for chronic obstructive pulmonary disease (COPD) — will be capped at $35 per month for eligible patients in ...
Drugmaker AstraZenecasaid it intends to cap out-of-pocket prices of four medicines used to treat asthma and chronic obstructive pulmonary disease (COPD) to $35 per month for many patients. Starting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback